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Introduction
The significance of protein quality control is demonstrated by a 
number of human disorders, such as cystic fibrosis and Parkin-
son’s disease, which can result from the accumulation of mis-
folded proteins (Ward et al., 1995; Meacham et al., 1999; Ardley 
et al., 2003; Olzmann et al., 2007; Metzger et al., 2008; Nakamura 
and Lipton, 2009). Therefore, understanding the mechanisms of 
misfolded protein metabolism, as well as cotranslational degra-
dation of defective proteins in mammalian cells (Qian et al., 
2006), is of primary importance. Hydrophobic residues that are 
normally buried in a variety of natively folded proteins may be 
exposed by protein misfolding and act as degrons to deliver the 
misfolded protein mainly to the ubiquitin–proteasome system for 
degradation (Metzger et al., 2008). Thus, ubiquitin-mediated pro-
tein quality control is essential for monitoring protein folding and 
endorsing misfolded and/or defective proteins for degradation/
aggregation (Johnston et al., 1998; Schubert et al., 2000; Lelouard 
et al., 2004). In the ubiquitin system, recognition and recruitment 
of defective proteins to the degradation machinery is a key step in 
the selective elimination of aberrant proteins (Finley et al., 2004; 
Hartmann-Petersen and Gordon, 2004; Elsasser and Finley, 
2005). Some cytosolic cochaperone proteins, such as CHIP, are 
known to be protein quality-control ubiquitin ligases that selec-
tively target aberrant proteins for proteasomal degradation by 
promoting their ubiquitination (Meacham et al., 2001). In addi-
tion, targeting of polyubiquitinated substrates to the 26S protea-
some is important because this process is thought to determine 
the final fate of defective proteins involved in various physiologi-
cal and pathological reactions (Voges et al., 1999; Hershko et al., 
2000; Madura, 2004; Hoeller et al., 2006). Previous studies have 
shown that the Rpn10 subunit of the 26S proteasome can recog-
nize polyubiquitinated substrates, and it is thought to play a role 
as a ubiquitin receptor for the 26S proteasome (Deveraux et al., 
1994; van Nocker et al., 1996; Kawahara et al., 2000; Wilkinson 
et al., 2001; Elsasser et al., 2004; Verma et al., 2004). Although it 
was believed that substrate recognition is an essential step in the 
proteasome-mediated degradation process, the role of Rpn10 re-
mained obscure after the observation that its deletion in yeast and 
nematodes does not influence the viability of cells and causes 
B
AG-6/Scythe/BAT3 is a ubiquitin-like protein that 
was originally reported to be the product of a novel 
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that BAG-6 is essential for not only model substrate deg-
radation but also the ubiquitin-mediated metabolism of 
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our in vivo and in vitro analysis shows that BAG-6 inter-
acts physically with puromycin-labeled nascent chain 
polypeptides  and  regulates  their  proteasome-mediated 
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results in the suppressed presentation of MHC class I on 
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efficiency of metabolism of defective ribosomal prod-
ucts. Therefore, we propose that BAG-6 is necessary for 
ubiquitin-mediated degradation of newly synthesized de-
fective polypeptides.
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Figure 1.  BAG-6 is essential for CL1 degron-dependent proteasomal degradation. (A) Schematic representation of the 3xFlag-tagged EGFP protein fused 
with CL1 degron used in this study. (B) CL1 degron-associated proteins identified in this study. After transfection of a 3xFlag-tagged EGFP-CL1 expression 
vector, HeLa cells were treated with 5 µM MG132 for 4.5 h. Proteins immunoprecipitated with antibody against Flag were subjected to SDS-PAGE and 
PMF analysis. 3xFlag-tagged EGFP immunoprecipitates were used as a negative control. (C) Knockdown of BAG-6 suppressed the degradation of the 
CL1 degron substrate. 3xFlag-tagged EGFP-CL1 was expressed in HeLa cells with two distinct shRNA vectors for BAG-6 (siRNA-1 and siRNA-2) or control 
siRNA. After 60 h of shRNA treatment, whole-cell extracts were prepared and subjected to immunoblot analysis with antibodies against Flag, BAG-6, 
and actin. (D) Expression patterns of endogenous BAG-6 protein in various adult mouse tissues (top). The anti-Hsp70/Hsc70 blot confirmed equal protein 
loading (bottom). (E) MG132 treatment stimulated the formation of a larger BAG-6 complex. Extracts of NIH3T3 cells were subjected to gel filtration 
with Superose 6, and the fractions were subjected to Western blotting with specific antibodies against BAG-6. Cells were cultured with (+) or without ()   639 BAG-6 mediates proteasomal degradation • Minami et al.
ubiquitin-dependent manner in yeast (Gilon et al., 1998; Metzger 
et al., 2008). We prepared a chimeric protein that fused the CL1 
degron to the C terminus of EGFP (designated EGFP-CL1)   
(Fig. 1 A) and confirmed that this fusion protein is highly unstable in   
HeLa cells and stabilized by proteasome inhibitors, such as MG132 
(unpublished data), indicating that EGFP-CL1 is indeed metabo-
lized by the ubiquitin–proteasome-dependent degradation path-
way in mammalian cells. Our peptide MS fingerprint analysis of 
EGFP-CL1 immunoprecipitates from MG132-treated HeLa cell 
extracts revealed a series of CL1-associated proteins including 
various chaperones, translation-related proteins, subunits of the 
26S proteasome, and BAG-6 (Fig. 1 B), suggesting that they 
might cooperatively participate in CL1 peptide metabolism. 
Among these proteins, we focused on BAG-6 as a novel key mol-
ecule for protein degradation because the Xenopus homologue of 
mammalian BAG-6 (called Scythe) has been reported to regulate 
apoptosis via the control of XEF1AO proteolysis in Xenopus em-
bryos (Minami et al., 2007). To examine the function of mam-
malian BAG-6 in CL1 metabolism, we suppressed endogenous 
BAG-6 expression by shRNA. As shown in Fig. 1 C, only a   
partial knockdown of BAG-6 blocked EGFP-CL1 degradation, 
indicating that BAG-6 is essential for the ubiquitin–proteasome-
mediated metabolism of EGFP-CL1 in HeLa cells (see also   
Fig. S1, A and B).
BAG-6 is a novel 26S proteasome-
associated protein
To detect the endogenous BAG-6 protein, we prepared a specific 
antibody and found that mammalian BAG-6 was mainly ex-
pressed in the brain and lymphoid tissues (Fig. 1 D). With this 
antibody, we examined whether BAG-6 forms complexes with 
other cellular proteins. We found that the endogenous BAG-6 
protein was eluted from gel filtration at a molecular weight of 
450 kD (Fig. 1 E, top). Unexpectedly, we found that treatment 
with MG132 stimulated the formation of a soluble, but much 
larger BAG-6 complex in HeLa cells (Fig. 1 E, bottom), and it 
apparently comigrated with 26S proteasomes, as determined by 
both gel filtration (Fig. S1 C) and glycerol density gradient frac-
tionation (Fig. S1 D). Because we previously found that the 
BAG-6 homologue in Xenopus interacted with a proteasomal 
subunit, we further examined whether endogenous BAG-6 pro-
tein interacted with the 26S proteasomal complex. Our results 
clearly showed that the 26S proteasome associated with anti–
BAG-6 immunoprecipitates (Fig. 1 F). Conversely, endogenous 
BAG-6  protein  could  be  coimmunoprecipitated  by  antibody 
against the Rpt6 subunit of the 26S proteasome (Fig. 1 G). In both 
precipitation experiments, the association between BAG-6 and 
the 26S proteasome was strengthened by treatment with MG132 
(Fig. 1, F and G). These observations suggest that mammalian 
BAG-6 is a novel member of 26S proteasome-associated proteins 
only mild or highly specific phenotypes (van Nocker et al., 1996; 
Shimada et al., 2006). These observations suggested the existence 
of functionally redundant routes in the substrate recruitment   
system. Indeed, several proteins, such as Rad23p and Dsk2p, are 
involved in the delivery of polyubiquitinated substrates to the 
proteasome because they can bind simultaneously with poly-
ubiquitinated substrates and the 26S proteasome (Kleijnen et al., 
2000; Wilkinson et al., 2001; Chen and Madura, 2002; Elsasser   
et al., 2004). Accordingly, these gene products in the substrate 
delivery pathway may play a largely redundant role (Elsasser et al., 
2004; Madura, 2004; Elsasser and Finley, 2005; Shimada et al., 
2006). However, owing to this complex redundancy, a complete 
picture of substrate recognition and recruitment to the 26S pro-
teasome in the ubiquitin system has not been adequately pre-
sented to date.
BAG-6–Scythe–BAT3 was originally identified as a novel 
gene located within the human major histocompatibility com-
plex (Banerji et al., 1990) that encodes the anti-apoptotic ubiquitin-
like protein (Thress et al., 1998, 1999; Desmots et al., 2005; 
Kikukawa et al., 2005; Sasaki et al., 2007), although its function 
and mechanism of action remain largely obscure. Our previous 
analysis revealed that Scythe, a BAG-6–homologous protein ex-
pressed in Xenopus embryos (Thress et al., 1998), binds to the 
proteasomal Rpn10c subunit via the N-terminal 436 residues 
and that this region is required for apoptotic control in Xenopus 
embryos (Kikukawa et al., 2005; Minami et al., 2007). Further-
more, our recent analysis indicated that the N terminus of Scythe 
regulates ubiquitin-mediated proteolysis of a pro-apoptotic pro-
tein (Minami et al., 2007), although how BAG-6 is involved in 
the ubiquitin-mediated pathway remains a mystery to be clari-
fied. In this study, we provide a set of evidence that BAG-6 is a 
novel  proteasomal  substrates-associated  protein.  Importantly, 
BAG-6–associated polyubiquitinated substrates are newly syn-
thesized defective ribosomal products (DRiPs) and BAG-6 plays 
a crucial role in their metabolism. BAG-6 offers a protective role 
against cell death induced by the accumulation of aberrant pro-
teins. Furthermore, we suggest that BAG-6 collaborates with   
immunoproteasomes to generate MHC class I presented anti-
genic peptides via targeted degradation of DRiPs and might play 
crucial roles in antigen presentation. These findings support the 
hypothesis that BAG-6 is a novel tethering factor that mediates 
selective elimination of defective nascent chain polypeptides in 
mammalian cells.
Results
BAG-6 is essential for the CL1  
degron–dependent degradation pathway
The hydrophobic CL1 peptide is known to function as an   
unstable degron that can be targeted to the 26S proteasome in a 
20 µM MG132 before harvesting. (F and G) BAG-6 was associated with the 26S proteasome in HeLa cells. (F) An antibody against BAG-6 was used to   
immunoprecipitate endogenous BAG-6 protein from extracts of HeLa cells cultured with (+) or without () 20 µM MG132 before harvesting. The precipitates 
were immunoblotted with antibodies to the 19S complex (Rpt5 subunit), 20S proteasome (5 subunit), and BAG-6. (G) Using an antibody against the 26S 
proteasome subunit Rpt6, endogenous 26S proteasomes were immunoprecipitated from HeLa cell extracts. HeLa cells were treated with 20 µM MG132 
for indicated periods. Immunoglobulin derived from nonimmune mouse serum was used as a negative control. The precipitates were immunoblotted with 
antibodies against BAG-6, 20S, and 19S complex (Rpt6 subunit).
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cells (Fig. 2 A and Fig. S2 A). The precipitation of polyubiqui-
tinated proteins was specific because preabsorption with an ex-
cess of antigen completely abolished the coimmunoprecipitation 
(Fig. 2 A). Immunoprecipitation of BAG-6 after denaturation 
with  SDS  never  coprecipitated  polyubiquitinated  moieties   
(Fig. S2 B), revealing polyubiquitinated identity as BAG-6–
bound proteins but not BAG-6 itself. Thus, BAG-6 appears not 
to be directly polyubiquitylated. Indeed, BAG-6 itself was sta-
ble in HeLa cells (Fig. S2, C–F). It has been reported that pro-
teins  of  the  BAG  family  interact  with  heat-shock  proteins 
(HSPs) via the C-terminal BAG domain (Demand et al., 2001; 
and that BAG-6 might be closely linked with ubiquitin-mediated 
protein degradation events (see also Fig. S1, E and F).
BAG-6 associates with polyubiquitinated 
proteasomal substrates
To examine the function of BAG-6 in the ubiquitin-mediated 
protein degradation pathway, we next immunoprecipitated en-
dogenous BAG-6 protein from HeLa cell extracts and blotted it 
with an antibody against ubiquitin. We found that a much larger 
amount of polyubiquitinated proteins coimmunoprecipitated 
with endogenous BAG-6 protein from extracts of MG132-treated 
Figure 2.  BAG-6 associates with polyubiquitinated proteasomal substrates. (A) Endogenous BAG-6 protein was affinity purified from extracts of MG132-
treated HeLa cells with an antibody against BAG-6, and the precipitates were immunoblotted with antibodies against ubiquitin and BAG-6. Ubiquitin 
coprecipitation of BAG-6 was abolished by preabsorption with an excess of BAG-6 antigen. (B) Endogenous BAG-6 protein precipitated from HeLa cell 
extracts was treated with 5 mM ATP (ATP-elute) before boiling in 1% SDS (SDS-elute). Each eluate was immunoblotted with antibodies against ubiquitin, 
Hsp70/Hsc70, and BAG-6. Cells were treated with (+) or without () 20 µM MG132 for 6 h before being harvested as indicated. Immunoglobulin derived 
from nonimmune rabbit serum was used in immunoprecipitation as a negative control. (C) Schematic representation of the BAG-6 deletion mutant proteins 
used in this study. The numbers denote corresponding amino acid numbers. (D) N-terminal 471 amino acids of BAG-6 were essential for the binding with 
polyubiquitinated proteins. The full-length (FL) form of 2S-tagged BAG-6 and its truncated derivatives were expressed in HeLa cells as indicated. Before 
harvesting, cells were treated with or without 10 µM MG132 for 12 h. Each form of BAG-6 was affinity purified with S-protein agarose, and the bound 
materials were blotted with antibodies against ubiquitin and S peptide.641 BAG-6 mediates proteasomal degradation • Minami et al.
EGFP-CL1 was degraded after incubation with ATP, which   
stabilizes/supports 26S proteasome function (Fig. S3 B). In con-
trast, polyubiquitinated EGFP-CL1 was stabilized when ATP 
was absent. When the active site within the 20S core particle was 
blocked by MG132, EGFP-CL1 degradation was inhibited, even 
in the presence of ATP (Fig. S3 B). Thus, these findings support 
the hypothesis that BAG-6 provides a platform that connects the 
26S proteasome and its ubiquitinated substrates to promote their 
efficient degradation.
BAG-6 is essential for metabolism of newly 
synthesized defective polypeptides
Identification of the client proteins of BAG-6 is critical to un-
derstanding the function of BAG-6. We observed only a slow 
degradation of ubiquitin conjugates in the lysate (not bound 
with BAG-6) after the removal of MG-132 (Fig. 3 A, input 
panel), in contrast to the rapid disappearance of polyubiqui-
tinated substrates on BAG-6 (Fig. 3 A, top IP panel). These 
observations indicate that polyubiquitinated substrates that 
associate with BAG-6 might be only a part of the proteasomal 
substrates and that BAG-6 substrates degrade much faster than 
do those existing as free from BAG-6. To elucidate the endoge-
nous client proteins of BAG-6, we analyzed the characteristics 
of polyubiquitin conjugates associated with BAG-6. We found 
that treatment with cycloheximide abolished most of the BAG-6–
associated polyubiquitinated species in MG132-treated cells 
(Fig. 3 C; top IP panel), whereas there was only a small reduc-
tion of ubiquitin conjugates in the lysate (existing as free from 
BAG-6) after addition of cycloheximide (Fig. 3 C, input panel). 
These observations suggest that a significant part of BAG-6– 
associated polyubiquitinated species is cycloheximide-sensitive 
(and thus newly synthesized) polypeptides that are stabilized 
with MG132 treatment in cells. It has been reported that more 
than 30% of newly synthesized polypeptides are recognized as 
defective proteins by the ubiquitin-dependent degradation path-
way (Schubert et al., 2000). Thus, we suspect that the primary 
target of BAG-6 might be defective ribosomal protein products 
(DRiPs) and that BAG-6 has a crucial function to support their 
efficient removal.
Inhibition of the proteasome-dependent proteolytic path-
way by treatment with MG132 induced gradual cell death   
(Fig. 3 D) with accumulation of polyubiquitinated defective pro-
teins. Although BAG-6 knockdown itself (up to 80%) did not sig-
nificantly affect cell viability and growth (Fig. S3, C–E; and 
unpublished data), we found that knockdown of BAG-6 signifi-
cantly enhanced the cytotoxicity of MG132 (and any other pro-
teasome inhibitors; Fig. 3 D). This result indicates that BAG-6 
knockdown renders cells more susceptible to MG132-induced 
death and that BAG-6 has an essential protective function against 
cell death induced by the accumulation of proteasomal substrates. 
Importantly, we found that the cytotoxicity enhanced by BAG-6 
siRNA was also drastically suppressed by treatment with cyclo-
heximide (Fig. 3 D). This observation further supports our con-
clusion that the effect of BAG-6 siRNA was mainly due to the 
excess  accumulation  of  newly  synthesized  defective  proteins. 
Thus, our data indicate that BAG-6 has a crucial function to   
metabolize defective ribosomal polypeptides.
Takayama and Reed, 2001). It is conceivable that HSP sub-
strate proteins might be modified by ubiquitin (Jiang et al., 
2001)  and  thus  coprecipitated  with  BAG-6. To  determine 
whether polyubiquitinated species that coimmunoprecipitated 
with BAG-6 were proteins that bound with HSP, BAG-6 immuno-
complexes were eluted by ATP (a procedure that stimulated 
the quantitative dissociation of Hsp70 from BAG-6; see Fig. 2 B, 
ATP  elute).  We  found  that  polyubiquitinated  proteins  re-
mained associated with BAG-6 after ATP elution but were re-
leased in the presence of SDS (Fig. 2 B, SDS elute). These 
results indicate that the majority of precipitated high molecular 
mass polyubiquitinated polypeptides are not Hsp70-associated 
client proteins or HSP itself. The results also suggest that a 
region other than the BAG domain is responsible for poly-
ubiquitin coprecipitation.
We next determined the region of BAG-6 required for inter-
action with polyubiquitinated proteins (Fig. 2, C and D). A mu-
tant form of BAG-6 lacking either the N-terminal UBL domain 
(by deletion of the N-terminal 148 residues, designated UBL, 
Fig. 2 C) or the C-terminal BAG domain bound polyubiquitinated 
proteins as efficiently as did full-length (FL) BAG-6 (Fig. 2 D and 
unpublished data), indicating that neither the UBL domain nor 
the BAG domain is essential for binding polyubiquitinated pro-
teins. In contrast, a mutant BAG-6 (designated N) with trunca-
tion of the N-terminal 471 amino acids (the region corresponding 
to the N-terminal 436 amino acids of Xenopus Scythe; Minami   
et al., 2007) did not bind polyubiquitinated proteins (Fig. 2 D). 
Consistent with this result, a fragment that exclusively encodes the   
N-terminal 471 amino acids (N471) coprecipitated polyubiqui-
tinated proteins as efficiently as did the full-length form of BAG-6 
(Fig. 2 D). These results indicate that the N-terminal 471 residues 
of BAG-6 are necessary and sufficient for its binding to polyubiq-
uitinated substrates.
We then attempted to determine the fate of polyubiqui-
tinated proteins associated with BAG-6 by “chasing” experi-
ments. HeLa cells were treated with MG132 (5 µM) for 4.5 h, 
the inhibitor was washed out (this time point being defined as 
time zero), and the cells were cultured in fresh medium without 
proteasome inhibitors (Fig. S3 A). Although BAG-6–associated 
polyubiquitinated proteins were evident at time zero (Fig. 3,   
A and B), they gradually disappeared after the removal of MG132. 
Within 4 h after chasing, no detectable polyubiquitinated pro-
teins coprecipitated with BAG-6 (Fig. 3, A and B). The dis-
appearance of polyubiquitinated substrates on BAG-6 does not 
necessarily mean their degradation but instead their dissociation 
from BAG-6. To determine whether BAG-6 was involved in pro-
tein degradation, we established a semi-vitro degradation assay 
system. In this experiment, 3xFlag-tagged EGFP-CL1 and 2S-
tagged BAG-6 were coexpressed in HeLa cells with the protea-
some inhibitor MG132. EGFP-CL1 was immunoprecipitated by 
an anti-Flag antibody from cell extracts (first IP), and the eluted 
proteins were then affinity purified using S-protein agarose beads 
(second precipitation). The isolated materials (containing EGFP-
CL1 and the 26S proteasome as a BAG-6 complex) were then 
incubated at 37°C in the presence or absence of ATP and/or 
MG132 in vitro and the stability of BAG-6–associated EGFP-
CL1 during the incubation periods was evaluated. We found that JCB • VOLUME 190 • NUMBER 4 • 2010   642
ubiquitin-positive cytoplasmic aggregates called ALIS (Lelouard 
et al., 2004). Interestingly, we also found that BAG-6 could   
be detected as cytoplasmic dots (Fig. 4 B, top panels) exclu-
sively in puromycin-treated cells, and these dots looked similar 
to puromycin-labeled protein aggregates (Fig. 4 B, bottom pan-
els). Indeed, we confirmed that the BAG-6–positive aggregates 
formed by puromycin treatment were co-ubiquitin stained 
(Fig. 4 C). These observations indicate that BAG-6 is intimately 
associated with cytoplasmic aggregates that are composed of 
polyubiquitinated nascent chain polypeptides in puromycin-
treated cells.
To estimate the impact of BAG-6 knockdown on formation 
of puromycin-induced aggregates, we compared aggregates with 
or without BAG-6 siRNA (Fig. 4, D–F). We found that cells with 
BAG-6 knockdown contain enlarged cytoplasmic aggregates 
compared with control siRNA cells (Fig. 4, D and E). In contrast, 
BAG-6 interacts with puromycin-labeled 
defective polypeptides
To investigate the relationship between BAG-6 and defective   
ribosomal products more directly, we examined whether BAG-6 
recognized  newly  synthesized  defective  polypeptides.  Puro-
mycin is an analogue of the 3 terminus of aminoacyl-tRNA that 
can be incorporated into newly synthesized polypeptides at their 
C termini, blocking further peptide elongation and thus produc-
ing truncated translational products (Fig. 4 A, bottom; Zhang et al., 
1997; Lelouard et al., 2004). We found that BAG-6 could be co-
immunoprecipitated by antibody against puromycin (Fig. 4 A, 
top IP panel). This result indicates that BAG-6 physically inter-
acts with puromycin-labeled nascent chain polypeptides. Re-
sults of our immunocytochemical analyses of BAG-6 after 
puromycin treatment further support this notion. It has been re-
ported that puromycin-labeled truncated proteins tend to form 
Figure 3.  BAG-6 associates with polyubiquitinated 
newly synthesized defective proteins. (A and B) Poly-
ubiquitinated  proteins  associated  with  BAG-6  were 
degraded  in  vivo.  HeLa  cells  were  treated  with 
MG132  (5  µM)  for  4.5  h,  the  inhibitor  was  then 
washed  out  (this  time  point  being  defined  as  time 
zero), and the cells were cultured in a fresh medium 
(without MG132) for the indicated times. After har-
vesting the cells, endogenous BAG-6 was immuno-
precipitated  and  the  coprecipitated  materials  were 
probed with an antibody against ubiquitin. Normal 
rabbit immunoglobulin was used as a negative con-
trol  for  the  immunoprecipitation  procedures.  “N” 
indicates no addition of MG132 to the cell culture. 
(C) Polyubiquitinated proteins associated with BAG-6 
were abolished by addition of the translation inhibitor 
cycloheximide (CHX). HeLa cells were treated with 
5 µM MG132 with or without 10 µg/ml or 20 µg/ml 
CHX  as  indicated  for  1  h  and  then  subjected  to   
immunoprecipitation using antibody against BAG-6. 
The immunoprecipitates were probed with antibodies   
against ubiquitin, 20S proteasome, and BAG-6. (D) De-
pletion of BAG-6 made HeLa cells more sensitive to 
proteasome inhibitor-induced cell death, but the ef-
fect of BAG-6 knockdown was abrogated by adding 
CHX.  48  h  after  treatment  with  siRNA,  cells  were 
treated with 5 µM MG132 for 24 h with or without   
10 µg/ml CHX, and cell viability was analyzed using   
an MTT cell counting system. The percent viability was 
normalized to the cells transfected with control siRNA 
without  MG132  treatment  (arbitrarily  assigned  a 
value of 100%). Error bars represent SD calculated 
from three experiments. P < 0.01, by t test.643 BAG-6 mediates proteasomal degradation • Minami et al.
BAG-6–mediated degradation of nascent 
chain polypeptides in vitro
We then established a reticulocyte lysate-based in vitro deg-
radation assay for artificial DRiPs. In this system, we used a   
puromycin-labeled, truncated luciferase (Luc163) that had been 
synthesized de novo as a model nascent chain polypeptide 
(Fig. S4 A). The Luc163 substrate, which was newly synthe-
sized in a rabbit reticulocyte lysate, was unstable in the extract 
the number of ubiquitin-positive aggregates was decreased with 
BAG-6 siRNA (Fig. 4 F). These results indicate that BAG-6 con-
trols the dynamics of aggregate metabolism. In addition, we 
found that BAG-6 knockdown accelerated puromycin-induced 
cell death (Fig. 4 G), indicating that BAG-6 has protective roles 
against nascent chain polypeptide-induced cell toxicity. Collec-
tively, the results indicate that BAG-6 might be an essential ele-
ment for the metabolism of nascent chain polypeptides.
Figure 4.  BAG-6 is involved in the metabo-
lism  of  puromycin-induced  nascent  chain 
polypeptides. (A) BAG-6 bound to truncated 
puromycin-labeled  proteins.  After  treatment 
with  5  µg/ml  puromycin  for  the  indicated 
times, HeLa cells were harvested, the puromycin- 
labeled  polypeptides  were  immunoprecipi-
tated from cell extracts with antibody against 
puromycin, and the precipitates were probed 
with antibody against BAG-6. (B and C) BAG-6 
localized on cytoplasmic dots after puromycin 
treatment. HeLa cells were treated with 5 µg/ml   
puromycin  for  2  h  and  extracted  with  1% 
Triton  X-100.  Fixed  cells  were  stained  with 
antibodies  against  BAG-6,  puromycin  (B), 
and ubiquitin (C). Note that a part of BAG-6   
also  localized  in  the  nucleus.  (D–F)  BAG-6 
controlled the dynamics of puromycin-induced 
aggregate formation. Puromycin-treated HeLa 
cells  with  BAG-6  siRNA  contained  enlarged 
but reduced numbers of ubiquitin-positive cyto-
plasmic aggregates. Error bars represent SD 
calculated from three experiments. (G) 48 h 
after siRNA treatment, cells were treated with 
puromycin  for  24  h  and  cell  viability  was 
analyzed with a cell counting kit. The percent 
viability was normalized to the cells without 
puromycin treatment.JCB • VOLUME 190 • NUMBER 4 • 2010   644
detected the accumulation of polyubiquitinated forms of Luc163   
in a MG132-treated rabbit reticulocyte lysate (Fig. S4, D and G). 
With this system, we showed that addition of antibody against 
(Fig. S4 B) and was stabilized by the addition of proteasome   
inhibitors (Fig. S4 C), indicating that Luc163 was metabolized 
via a ubiquitin-dependent pathway. In accordance with this, we 
Figure 5.  BAG-6 provides a platform that is necessary for linking puromycin-labeled defective protein with degradation machinery. (A) Addition of 
antibody against BAG-6 inhibited the degradation of puromycin-labeled, truncated luciferase in vitro. A messenger RNA encoding the 3xFlag-tagged 
N-terminal 163 residues of luciferase (Luc163) was incubated in a rabbit reticulocyte lysate chasing with 2 mM puromycin addition. After addition of 
50 µg/ml anti–BAG-6 antibody, cycloheximide (CHX) chase analysis was performed, and lysates were harvested at the indicated times and probed with 
antibodies against Flag and Rpt6 to evaluate the stability of puromycin-labeled Luc163 (Luc163). Non-immune rabbit IgG or antibody against BAG-6 
that was preabsorbed with an excess amount of recombinant antigen was used as a negative control. (B) Addition of antibody against BAG-6 inhibited 
ubiquitination of puromycin-labeled, truncated luciferase. Blot with Flag-Luc163 and Rpt6 are indicated as loading controls. (C) Immunoprecipitation of 
in vitro translated Luc163 with anti-Flag M2 beads coprecipitated endogenous BAG-6 and Hsp70 from lysates. (D) BAG-6 provided a platform for the 
targeted degradation of Luc163. Endogenous BAG-6 was immunoprecipitated from a rabbit reticulocyte lysate that was translating 3xFlag-tagged Luc163. 
The precipitated immunocomplex was further incubated in the presence (+) or absence () of 5 mM ATP, ubiquitin, and 25 µM MG132 at 37°C for 2 h 
as indicated. After incubation, the precipitated complexes were subjected to Western blot analysis with an antibody against Flag to examine the stability 
of Luc163 on BAG-6 during the incubation periods. (E) Endogenous BAG-6 was immunoprecipitated (first IP) as in D, and the precipitated complex was 
incubated with MG132 under the conditions indicated. After incubation, the complexes were denatured by SDS and diluted samples were further subjected 
to precipitation with anti-Flag M2 agarose (second IP). Precipitated, Flag-tagged Luc163 was blotted with antibody against ubiquitin to estimate the extent 
of its modification with ubiquitin.645 BAG-6 mediates proteasomal degradation • Minami et al.
suggesting that peptide production by the proteasome is limited 
after BAG-6 down-regulation.
To further verify the expression of MHC class I with an-
other independent method, we performed an experiment to   
label the cell surface with biotin. In this experiment, cell surface 
proteins were biotinylated after siRNA, affinity purified with 
avidin beads, and blotted with antibody against MHC class I. 
As shown in Fig. 6 D, the abundance of biotinylated MHC 
class I molecules was clearly reduced with BAG-6 siRNA. The 
reduction of cell surface MHC molecules is not caused by sim-
ple defects in the peptide transport system inside cells, because 
the amount of EGF receptor protein (EGFR) was not affected 
by BAG-6 knockdown but was reduced by brefeldin A, a drug 
that is known to block anterograde protein transport from the 
ER to the Golgi. Thus, all of our experiments showed that 
BAG-6 is essential for supplying antigenic peptides to the 
immune system.
Finally, we also provided evidence that BAG-6 could be as-
sociated with immunoproteasomes, the principal cytosolic prote-
ases used for generating MHC class I peptide ligands (Monaco 
and Nandi, 1995; Tanaka and Kasahara, 1998; Rock and Goldberg, 
1999), after induction by treatment with interferon- (Fig. S5 A). 
Although our results showed that BAG-6 could be associated 
with constitutive 26S proteasome as well (Fig. 1, F and G), these 
observations suggest that BAG-6 collaborates with immuno-
proteasomes to generate antigenic peptides via targeted degrada-
tion of defective ribosomal products and might play a crucial role 
for antigen presentation in immune response.
Discussion
The CL1 degron used in this study was originally identified in a 
screen for a genomic sequence that destabilized the cytosolic pro-
tein Ura3p by targeting it for degradation via Ubc6p/Ubc7p in the 
yeast Saccharomyces cerevisiae (Gilon et al., 1998). Metzger et al. 
(2008) reported that CL1 represents a frame-shifted region of the 
yeast PMD1 gene and that it contains a strongly hydrophobic   
region and thus may resemble a misfolded protein when it is   
exposed. Therefore, a study using a CL1 degron might reveal 
mechanisms for the targeted removal of improper translational 
products. A previous study indicated that Ura3p-CL1 degradation 
in yeast is dependent on the molecular chaperones Ydj1p (a DnaJ 
homologue) and Ssa1p (Hsp70 homologue) as well as the protea-
some (Metzger et al., 2008). In accordance with the results of that 
study, we found that the CL1 degron could interact with human 
homologues of DnaJ, Hsp70, and 26S proteasome subunits in 
HeLa cells (Fig. 1 B). Furthermore, we identified BAG-6 as a 
novel mammalian CL1-associated protein. This observation sug-
gested that BAG-6 may participate in the metabolism of misfolded 
proteins for proteasomal degradation. Indeed, we found in this 
study that BAG-6 recognized a CL1 degron substrate and sup-
ported its proteasomal degradation. We showed evidence that not 
only a CL1 model substrate but also newly synthesized polyubiq-
uitinated polypeptides were associated with BAG-6 after protea-
some inhibition (Fig. 3 C). All of our data suggest that BAG-6 
provides a transient platform that is necessary for linking the 26S 
proteasome and its defective substrates for targeted degradation.
the N terminus of BAG-6 to the extracts blocked both degradation 
(Fig. 5 A) and polyubiquitin modification (Fig. 5 B and Fig. S4 E) 
of Luc163. In the reticulocyte lysate, Luc163 was associated with 
BAG-6 (Fig. 5 C). After isolation of the BAG-6 complex from ly-
sates by anti–BAG-6 immunoprecipitation, the immunocomplex 
was incubated at 37°C in the presence or absence of MG132   
and/or ATP in vitro and the stability of BAG-6–associated Luc163 
during the incubation periods was evaluated (Fig. 5 D). We found 
that isolated Luc163 in the complex was degraded after incuba-
tion with ATP (which stabilizes/supports 26S proteasome func-
tion) and ubiquitin. In contrast, Luc163 was stabilized when ATP 
was absent. When the 26S proteasome was blocked by MG132, 
Luc163 degradation was inhibited, even in the presence of ATP 
(Fig. 5 D). The situation is similar in polyubiquitination of 
Luc163. Incubation of the BAG-6–Luc163 immunocomplex in 
vitro with ATP, ubiquitin, and MG132 enhanced polyubiquitin 
modification of Luc163 on BAG-6 (Fig. 5 E and Fig. S4 F). Thus, 
these findings support the idea that BAG-6 provides a platform 
that connects degradation machinery and nascent chain polypep-
tides to promote their efficient degradation.
BAG-6 knockdown blocks the cell surface 
presentation of MHC class I
All of our observations support the idea that BAG-6 is essential 
for selective elimination of defective ribosomal products. It is 
reported that degradation products of DRiPs are the major source 
of peptide ligands presented on the cell surface MHC class I 
molecules of the major histocompatibility complex (Reits et al., 
2000; Schubert et al., 2000; Khan et al., 2001; Yewdell and   
Bennink, 2001; Yewdell et al., 2003). If BAG-6–mediated pro-
cessing of DRiPs is a major source of peptide ligands for MHC 
class I molecules, then knockdown of BAG-6 function in vivo 
should rapidly decrease the peptide supply and should block the 
cell surface presentation of MHC class I molecules because pep-
tide binding is required for the rapid export of class I molecules. 
To directly examine whether BAG-6 knockdown affected the 
presentation of MHC class I molecules, we performed live-cell 
flow cytometric analysis with FITC-labeled anti–HLA-ABC anti-
body (W6/32). As our positive controls, we confirmed that treat-
ment of HeLa cells with 10 µM MG132 increased the populations 
of FITC-negative cells (Fig. 6, A–C). Treatment with 10 µg/ml   
cycloheximide (CHX) also reduced the mean of fluorescence in-
tensity of FITC-HLA-ABC on the surface of HeLa cells (Fig. 6, 
A and C). These results support a previous hypothesis that   
proteasome-mediated degradation of newly synthesized protein 
is essential for MHC class I presentation (Yewdell et al., 1996; 
Rock and Goldberg, 1999; Reits et al., 2000; Khan et al., 2001). 
In the case of BAG-6 knockdown, we found that the populations 
of FITC-negative cells increased significantly (Fig. 6, A and B).   
A quantitative evaluation of the mean of fluorescence intensity 
of FITC-HLA-ABC on the surface of HeLa cells indicated that 
the fluorescence decreased less than half in BAG-6 knockdown 
samples compared with the negative control (Fig. 6 C). These re-
sults suggest that knockdown of BAG-6 results in the suppres-
sion of MHC class I cell surface presentation. In addition, we 
found that an excess of exogenously supplied antigenic peptides 
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(Johnston et al., 1998; Bence et al., 2001; Ardley et al., 2003). 
Because we found that BAG-6 interacted with polyubiquitinated 
proteins (Fig. 2; and Fig. 3) and that a part of BAG-6 moved to the 
insoluble fractions after treatment with MG132 (Fig. S5 B),   
we investigated whether BAG-6 colocalized with an aggresome.   
As shown in Fig. S5 C, confocal microscopic observation revealed 
that the treatment of MG132 resulted in the formation of a large 
perinuclear structure and that BAG-6 accumulated on this aggre-
gate. Importantly, we found that BAG-6–positive aggregates were 
coimmunostained with either polyubiquitin or the intermediate 
filament protein vimentin, markers for aggresome formation 
(Johnston et al., 1998), in the presence of MG132 (Fig. S5 C). 
It has been reported that 25% of rapidly degraded poly-
peptides (RDPs) lose their solubility within an hour of blocking 
proteasome activity (Qian et al., 2006). The expression of BAG-6 
was diffuse and soluble in normal HeLa cells, whereas treat-
ment with MG132 significantly increased the amount of BAG-6 
in the detergent-insoluble fraction (Fig. S5 B). These results 
support the notion that the BAG-6 protein in the soluble fraction 
moves to and accumulates in the insoluble aggregates associ-
ated with ubiquitinated RDPs during proteasomal dysfunction. 
It has been reported that polyubiquitinated, aggregation-prone 
misfolded proteins are transported on microtubules to the MTOC 
and then form large perinuclear insoluble aggregates/aggresomes 
Figure 6.  BAG-6 modulates expression of MHC class I molecules on the cell surface. (A and B) Live-cell flow cytometric analysis of HeLa cells with FITC-
labeled antibody against MHC class I that recognizes cell surface HLA-ABC antigen. As positive controls, the results of treatment with 10 µM MG132   
(A and B) and 10 µg/ml CHX (A) are shown. The data were obtained by linear scale analysis (A) and by log scale analysis (B). The flow cytometric pattern 
of negative control siRNA is indicated as a red line, and those after treatment with BAG-6 siRNA, MG132, and CHX are indicated with black lines (A). 
BAG-6 knockdown was performed with two independent duplex siRNAs as described in Materials and methods, and both siRNA gave a similar result. 
Representatives are results with duplex siRNAs of BAG-6-2 (5-ATGATGCACATGAACATTC-3). (C) Quantitative evaluations of the mean of fluorescence 
intensity of FITC-HLA-ABC on the surface of HeLa cells. Antigenic peptide mixture was pulsed with cells at 50 µM for 16 h. The data shown are the results 
of at least three independent experiments. (D) Biotin-labeling experiments. Cell surface proteins were biotinylated and affinity purified with avidin beads 
and blotted with antibody against MHC class I. Knockdown of BAG-6 reduced the expression of MHC class I on the cell surface, whereas the amount of 
EGF receptor (EGFR) on the cell surface was not affected. Brefeldin A treatment was used as a positive control for general suppression of transport of MHC 
class I and EGFR to the cell surface. Actin blots for whole-cell lysates (WCL) were used as a loading control for whole cellular proteins.647 BAG-6 mediates proteasomal degradation • Minami et al.
replace constitutively expressed subunits in newly assembled 
proteasomes to create immunoproteasomes, which appear to be 
better at producing peptides favored by MHC class I molecules 
(Tanaka and Kasahara, 1998). It is worth recalling that BAG-6 
was originally described as an MHC-encoded gene product   
(Banerji et al., 1990) and that its expression is apparently enriched 
in lymphoid tissues (this paper; Fig. 1 D). Although we have not 
yet detected obvious induction of BAG-6 by interferon-, we 
present here an interesting possibility that BAG-6 is a novel fac-
tor that modulates immune responses via DRiP-mediated anti-
gen presentations.
The role of BAG-6 in apoptotic cell death appears to be an 
area of controversy. In several previous studies, BAG-6 has been 
shown to be required for the induction of apoptosis in response to 
a variety of stimuli, and the loss of BAG-6 is associated with pro-
tection against apoptosis induced by calcium overloading in the 
ER as well as by menadione and thapsigargin (Desmots et al., 
2008). Currently, we do not exactly know how the reported apop-
totic function of BAG-6 is linked to the proteolytic function iden-
tified in this study. However, the region that is required for 
apoptotic control (N-terminal 436 residues in Xenopus Scythe–
BAG-6; Minami et al., 2007) superficially overlaps with the re-
gion of substrate recognition in mammalian BAG-6. In addition, 
our previous study indicated that the N-terminal region of Scythe–
BAG-6 interacts with XEF1AO, a maternal form of polypeptide 
elongation factor that was suggested to be a potential inducer of 
apoptosis in vertebrates (Minami et al., 2007). The binding stimu-
lates polyubiquitin modification and subsequent degradation of 
XEF1AO in Xenopus embryos. In addition, we found in this 
study that BAG-6 provided protection against cell death induced 
by MG132 and puromycin treatment in mammalian cells. These 
observations imply that BAG-6–mediated modification of protein 
degradation is, at least in part, important for apoptotic control 
caused by the accumulation of aggregation-prone defective pro-
teins. Because aggregated proteins with polyubiquitin have been 
proposed to be central to the pathology of a number of neurologi-
cal diseases (Bence et al., 2001; Taylor et al., 2002; Ardley et al., 
2003), we are also interested in the possibility that BAG-6 is in-
volved in protein quality control in the neural system.
In the ubiquitin-dependent protein degradation pathway, 
the substrate sorting process depends on the cooperation of 
chaperone machineries and ubiquitin chain recognition factors 
(Hartmann-Petersen and Gordon, 2004; Verma et al., 2004; 
Richly et al., 2005; Westhoff et al., 2005). These factors sequen-
tially support the process through protein–protein interactions 
and thereby escort substrate recognition, ubiquitination, and 
ubiquitin–protein conjugate presentation to the proteasome 
(Richly et al., 2005). Although we do not fully know what kinds 
of ubiquitin chain recognition factors and ubiquitination ma-
chinery are associated with BAG-6 at present, we favor the idea 
that BAG-6 may possess roles in ubiquitin modification of teth-
ered substrates. We observed that there was an inexplicable   
increase in BAG-6–bound ubiquitin conjugates for 1 h after 
MG132 removal (Fig. 4 B). In our previous study, we reported 
that Scythe–BAG-6 expression stimulates polyubiquitin modifi-
cation of XEF1AO substrate (Minami et al., 2007). These obser-
vations suggest that the BAG-6–Scythe complex plays a role in 
Our observations suggest that BAG-6 is functionally linked with 
the aggresome at the time of proteasome inhibition (Fig. S5 D).
Schubert et al. (2000) reported that 30% or more of newly 
synthesized proteins are destroyed by proteasomes of their syn-
thesis. These unstable nascent polypeptides that emerge from the 
ribosome into the cytosol were designated as defective ribosomal 
products (Yewdell et al., 1996). DRiPs are polypeptides that fail 
to attain a stable conformation because of errors in translation, 
folding, and post-translational modification as well as errors in 
transcription and mRNA processing. Puromycin is mistakenly 
inserted during protein synthesis by the ribosome in place of 
normal amino acids, resulting in truncated DRiPs containing the 
drug at their C termini (Vazquez, 1974; Lelouard et al., 2004). 
Our  immunocytologic  and  immunoprecipitation  experiments 
provided evidence that BAG-6 could associate with puromycin-
labeled defective nascent polypeptides in vivo. We also showed 
that BAG-6 controlled in vivo formation of puromycin-induced 
aggregation structures. Furthermore, our in vitro analysis clearly 
showed that puromycin-labeled truncated luciferase, a model 
DRiP substrate, was ubiquitinated and degraded on BAG-6 in 
rabbit reticulocyte lysates. All of these observations strongly 
support our conclusion that mammalian BAG-6 is essential for 
selective elimination of defective nascent chain polypeptides.
It has been shown that newly synthesized proteins are the 
major source of peptide ligands presented by MHC class I mole-
cules of the major histocompatibility complex on the cell surface 
(Townsend et al., 1986; Anton et al., 1997; Khan et al., 2001).   
It has been reported that blocking protein synthesis for 30 min is 
sufficient  to  deplete  cells  of  most  TAP-transported  antigenic 
peptides (Reits et al., 2000). Because a similar degree of deple-
tion is reported to be achieved within 15 min of blocking protea-
somes, the primary source of peptides is from proteins in the first 
15 min of their synthesis (Reits et al., 2000). To date, there is con-
siderable evidence that a significant source of self and viral pep-
tides is DRiPs, which consist of prematurely terminated and/or 
misfolded polypeptides (Yewdell et al., 1996, 2003; Yewdell, 
2002; Princiotta et al., 2003). If BAG-6–mediated processing of 
DRiPs is a major source of peptide ligands for MHC class I mol-
ecules, then blocking BAG-6 function should rapidly decrease 
the peptide supply and should subsequently slow the cell surface 
presentation of MHC class I molecules because peptide binding 
is required for the rapid export of class I molecules. That is the 
reason why we examined the cell surface presentation of MHC 
molecules in this study (Fig. 6). Both our FACS and biochemical 
analyses clearly showed that knockdown of BAG-6 resulted in 
the suppression of MHC class I cell surface presentation without 
affecting the intracellular protein transport system. These results 
also support our hypothesis that BAG-6 is essential for supply-
ing antigenic peptides to the immune system. In good agreement 
with this observation, we found that BAG-6 was associated with 
immunoproteasome complexes after treatment with interferon- 
(Fig. S5 A). The initial evidence implicating immunoprotea-
somes in antigen processing was the discovery that the MHC re-
gion contains genes that encode two proteasome subunits and 
that their expression is controlled by cytokines released by acti-
vated T cells (Michalek et al., 1993; Monaco and Nandi, 1995; 
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(MBL), anti-tubulin (ICN), anti-Chk2 (Santa Cruz Biotechnology, Inc.), anti-
MHC class I (Santa Cruz Biotechnology, Inc.), anti-EGFR (Santa Cruz Bio-
technology, Inc.), anti-GST (Santa Cruz Biotechnology, Inc.), anti-vimentin 
(Santa Cruz Biotechnology, Inc.), and anti–human HLA-ABC monoclonal 
antibody W6/32 (Bay Bioscience Co., Ltd.). Anti-puromycin antibody is   
a gift from Peter Walter at University of California, San Francisco (San 
Francisco, CA).
Identification of CL1-associated proteins
An  expression  vector  encoding  3xFlag-tagged  EGFP-CL1  was  trans-
fected into HeLa cells. After 4.5 h treatment with 5 µM MG132, cells 
were harvested and crushed with IP buffer. Using anti-Flag M2 agarose 
beads (Sigma-Aldrich), EGFP-CL1 were immunopurified and subjected 
to SDS-PAGE analysis. 3xFlag-tagged EGFP was used as a negative 
control.  PMF  analysis  was  performed  with  Voyager  Biospectrometry 
Workstation  DE-PRO  (PerSeptive  Biosystems)  as  described  previously 
(Minami et al., 2007).
Gene knockdown experiments
For knockdown analysis of BAG-6 in Fig. 1 C, the oligonucleotides encod-
ing two independent targeted sequences of BAG-6 (targeted sequence of 
siRNA-1: 5-TGGGTCCCTATTATCCAGC-3, siRNA-2: 5-TTTCTCCAAGAG-
CAGTTTA-3) were inserted into the pSUPER vector (Oligo Engine). The 
plasmids for siRNA were transfected to HeLa cells. 60 h after treatment of 
siRNA, cells were subjected to Western blot analyses. For other knockdown 
experiments, two independent duplex siRNAs encoding the targeted se-
quences of BAG-6 (BAG-6-1: 5-TTTCTCCAAGAGCAGTTTA-3, BAG-6-2: 
5-ATGATGCACATGAACATTC-3)  were  synthesized  (SIGMA  Genosys) 
and used with Lipofectamine 2000 (Invitrogen) according to the protocol 
provided by the manufacturer. Negative control siRNA was purchased from 
Invitrogen. The efficacies of each siRNA were verified by immunoblot and 
RT-PCR (Fig. S3, D and E) or immunocytochemical observations with anti-
BAG-6 antibody.
Gel filtration analysis of the cell extracts of NIH3T3
Extracts of NIH3T3 cells were subjected to gel filtration on a column of   
Superose 6 HR 10/30 (GE Healthcare) in buffer A (10 mM Tris-HCl, pH 7.5, 
50 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 1% Tween 20, 10% glycerol, 
2 mM ATP, 1 mM dithiothreitol, 10% glycerol, 1 mM PMSF, 3 µg/ml pep-
statin A, 5 µg/ml aprotinin, 10 mM N-ethylmaleimide, and 25 µM MG132) 
at a flow rate of 0.25 ml/min. Fractions of 0.5 ml were collected and sub-
jected to SDS-PAGE, followed by Western blotting. Gel Filtration LMW/
HMW Marker kits (GE Healthcare) were used as molecular mass standard 
proteins for gel filtration.
Microscopic observations
For immunocytochemical observations of cultured cells, HeLa cells were 
grown on micro coverglass (Matsunami), fixed by incubating in 4% para-
formaldehyde,  and  were  then  permeabilized  with  0.1%  Triton  X-100. 
Fixed cells were blocked with 1% bovine serum albumin in PBS and re-
acted with a series of primary antibodies at room temperature for 1 h.   
Alexa 594–conjugated anti–rabbit IgG antibody (Invitrogen) and FITC- 
conjugated anti–mouse antibody (Jackson ImmunoResearch Laboratories, 
Inc.) were used as secondary antibodies at dilutions of 1:800. To observe 
the nucleus, cells were stained with 2.5 µg/ml DAPI in PBS at the time of 
antibody staining. Immunofluorescent images were obtained with an invert 
confocal microscopy system (LSM510; Carl Zeiss, Inc.).
Cell viability assay
HeLa cells were treated with BAG-6–specific siRNA or negative control 
siRNA (Invitrogen). After 12 h, cells were plated in 96-well plates at a den-
sity of 10
4 cells/well and cultured for a further 72 h with or without treat-
ment of 5 µM MG132 or 5 µg/ml puromycin for the indicated time. Cell 
viability was determined using a cell counting kit 8 (Dojindo) according to 
the protocol provided by manufacturer. The absorbance of 450 nm was 
measured by a densitometer (CS-9300PC; Shimadzu).
Rabbit reticulocyte lysate-based preparation of model DRiP substrate
Flag-tagged luciferase gene in mammalian expression vector (pCI-neo; Pro-
mega) was digested with restriction enzyme Bsp1407I. Bsp1407I exclu-
sively cut the middle of luciferase ORF at the position of 163 residue of its 
encoding luciferase protein. Using this linearized DNA as a template, mRNA 
was  synthesized  in  vitro  using  mMESSAGE  smMACHINE  (Applied  Bio-
systems). The synthesized mRNAs was added to rabbit reticulocyte lysate 
and incubated at 26°C for 40 min, followed by an additional 20-min incu-
bation with 2 mM puromycin, resulting in a production of puromycin-labeled 
modification of polyubiquitin chains. We suggest that BAG-6 
provides a transient platform that links the ubiquitinating ma-
chinery, the 26S proteasome, and its newly synthesized substrates 
to promote their efficient destruction. In any case, we have pre-
sented the first evidence that BAG-6–Scythe–BAT3 is a novel 
polyubiquitinated substrate-associated protein, and our results 
shed light on the importance of BAG-6 in the degradation of de-
fective proteasomal substrates. Elucidation of the involvement of 
BAG-6 in the regulation of viral infections and/or onset of neuro-
degeneration caused by defects in the metabolism of DRiPs 
should be the next big challenge in understanding the signifi-
cance of BAG-6 in the development of various human diseases.
Materials and methods
Plasmid construction
The cDNAs of BAG-6 were amplified by PCR from the library prepared 
from NIH3T3 and HeLa cells. The PCR products of BAG-6 were digested 
with SalI–NotI and inserted into the pCI-neo-3xFlag or pCI-neo-2S vectors 
for expression in cultured cells. It should be noted that pCI-neo-3xFlag and 
pCI-neo-2S expression vectors contain three repeats of a Flag tag or two 
repeats of an S peptide sequences, respectively, at the N-terminal regions 
of their products. The truncated and mutated versions of BAG-6 were con-
structed by PCR and cloned into appropriate pCI-neo vectors (Promega). 
The synthetic oligonucleotide encoding the CL1 peptide (ACKNWFSSLSH-
FVIHL; Gilon et al., 1998) was inserted into the EcoRI site of pCI-neo-
3xFlag-EGFP expression vector. Each vector was used for experiments after 
verification of the sequence of inserted DNA.
Mammalian cell culture and transfection
HeLa, Neuro2a, and NIH3T3 cells were cultured in DME (Sigma-Aldrich) 
supplemented with 10% heat-inactivated calf serum at 37°C under a 5% 
CO2 atmosphere. Transfection to HeLa cells was performed according to 
the standard calcium phosphate precipitation protocol. The total amount of 
plasmid DNA was adjusted to 2 µg with an empty vector. At 24 h after 
transfection,  the  cells  were  harvested  and  subjected  to  immunological 
analysis unless otherwise noted.
Immunological analysis
An anti–BAG-6 antibody was prepared as follows. 200 g of bacterially 
produced Xenopus BAG-6 (N-terminal 436 amino acids) was mixed and 
emulsified with an equal amount of TiterMaxGold (TiterMax USA, Inc.) and 
then inoculated into a rabbit. The antibody was obtained after three rounds 
of immunization at 1-wk intervals and used after affinity purification. We 
confirmed that this antibody can efficiently recognize mammalian BAG-6.
For immunoprecipitation analysis, cultured cells were washed with 
ice-cold phosphate-buffered saline and lysed with immunoprecipitation (IP) 
buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 
1% Tween 20, 10% glycerol, 1 mM dithiothreitol, 1 mM phenylmethane-
sulfonyl fluoride (PMSF), 3 µg/ml pepstatin A, 5 µg/ml aprotinin, 10 mM   
N-ethylmaleimide, and 25 µM MG132. The lysate was sonicated for 1 s 
and centrifuged at 20,000 g for 20 min at 4°C, and the resulting super-
natant was incubated with 3 µl of anti-Flag M2-agarose beads (Sigma- 
Aldrich), 5 µl of S-protein agarose beads (EMD), or anti–BAG-6 antibody 
stabilized to Protein A–Sepharose beads (GE Healthcare) for 2 h at 4°C. 
After the beads had been washed four times with the IP buffer, the precipi-
tated immunocomplexes were subjected to SDS-PAGE. ATP elution was per-
formed as described previously (Demand et al., 2001).
For Western blotting, the whole-cell lysate and immunoprecipitates 
were separated by SDS-PAGE and transferred onto nitrocellulose mem-
branes (Bio-Rad Laboratories). The membranes were immunoblotted with 
specific antibodies as indicated and then incubated with horseradish per-
oxidase–conjugated  antibody  against  mouse  or  rabbit  immunoglobulin 
(GE Healthcare), followed by detection with ECL Western blotting detection 
reagents (GE Healthcare).
The following antibodies were used for immunological analyses in 
this study: anti-19S complex (Rpt1, Rpt5, and Rpt6 subunits; Thermo Fisher 
Scientific and Enzo Life Sciences, Inc.), anti-20S proteasome (5 and 1i 
subunit; Thermo Fisher Scientific and Enzo Life Sciences, Inc.), anti-S pep-
tide (Santa Cruz Biotechnology, Inc.), anti-Flag tag (Sigma-Aldrich), anti-
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truncated luciferase as a model nascent chain polypeptide. Flag-tagged full-
length luciferase without puromycin treatment was used as a non-DRiP con-
trol polypeptide.
Assay for presentation of MHC class I on the cell surface
For FACS analysis, knockdown experiments were performed with two inde-
pendent duplex siRNAs encoding the targeted sequences of BAG-6 (BAG-6 
siRNA-1: 5-TTTCTCCAAGAGCAGTTTA-3, BAG-6 siRNA-2: 5-ATGATG-
CACATGAACATTC-3) with Lipofectamine 2000 (Invitrogen). After 72 h of 
siRNA transfection, 10
6 HeLa cells were harvested and probed with FITC- 
labeled anti–human HLA-ABC monoclonal antibody W6/32 (Bay Biosci-
ence Co., Ltd.) in PBS (containing 10% FBS) at 4°C for 30 min. As positive 
controls, HeLa cells were treated with 10 µM MG132 or 10 µg/ml cyclo-
heximide for 22 h (MG132) or 8 h (CHX), respectively, before harvesting. 
Exogenously  supplied  peptides  (YVIKVSARV  for  HLA-A*6802,  VQRL-
NATGY for HLA-B*1503, CCFHCQVC for HLA-Cw*1203) were synthe-
sized by SIGMA Genosys and were pulsed with cells at 50 µM for 16 h 
before harvesting. Negative control siRNA was purchased from Invitrogen. 
Living-cell FACS analyses were performed with a FACSCalibur flow cytome-
ter (Becton Dickinson) by ReproCELL, Inc.
Biochemical labeling experiments were performed as follows. After 
72 h of siRNA transfection, HeLa cells were harvested and the cell surface 
proteins were biotinylated. Immediately after cell lysis with biotin lysis buf-
fer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 1% Triton X-100), cell 
surface–biotinylated proteins were affinity purified with avidin beads. The 
bound cell surface proteins were detected by antibodies against MHC 
class I and EGF receptor (EGFR; control of cell surface proteins). Brefeldin 
A treatment at 1 µg/ml for 4 h was used as a positive control for the sup-
pression of the transport of MHC class I and EGFR to the cell surface. Anti-
actin blot was used as a loading control.
Online supplemental material
Fig. S1 shows our additional data that BAG-6 is essential for CL1 degron-
dependent proteasomal degradation. Fig. S2 demonstrates that BAG-6 is 
a stable protein that associates with polyubiquitinated substrates. Fig. S3 
shows that polyubiquitinated proteins associated with BAG-6 are destined 
for degradation. Fig. S3 also shows the efficacies of BAG-6 knockdown. 
Fig. S4 describes our proteasome-dependent nascent polypeptide chain 
degradation system. Fig. S5 demonstrates that BAG-6 interacts with immuno-
proteasome and with aggresome. Online supplemental material is avail-
able at http://www.jcb.org/cgi/content/full/jcb.200908092/DC1.
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